Retinal nerve fibre layer attenuation: Clinical indicator for vigabatrin toxicity

Acta Ophthalmologica

Volumn 89, Issue 5, 2011, Pages 452-458

  Moseng, Linda ^a   Sæter, Mali ^a   Mørch Johnsen, Gunhild H ^a   Hoff, Jana M ^b   Gajda, Anna ^c   Brodtkorb, Eylert ^a   Midelfart, Anna ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

epilepsy; optical coherence tomography; retinal nerve fibre layer thickness; vigabatrin; visual field defects

Indexed keywords

BRIVARACETAM; CARBAMAZEPINE; CLOBAZAM; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; RETIGABINE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG INDUCED DISEASE; EPILEPSY; FEMALE; FOCAL EPILEPSY; HUMAN; MALE; OPTICAL COHERENCE TOMOGRAPHY; PERIMETRY; PRIORITY JOURNAL; RETINA NERVE CELL; VISUAL FIELD DEFECT;

ADULT; ANTICONVULSANTS; EPILEPSIES, PARTIAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NERVE FIBERS; RETINA; TOMOGRAPHY, OPTICAL COHERENCE; VIGABATRIN; VISION DISORDERS; VISUAL FIELDS;

EID: 79960411340     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2010.02077.x     Document Type: Article

References (29)

1. Buncic JR, Westall CA, Panton CM, Munn JR, MacKeen LD, &, Logan WJ, (2004): Characteristic retinal atrophy with secondary "inverse" optic atrophy identifies vigabatrin toxicity in children. Ophthalmology 111: 1935-1942. (Pubitemid 39311851)
2. Chai SJ, &, Foroozan R, (2007): Decreased retinal nerve fibre layer thickness detected by optical coherence tomography in patients with ethambutol-induced optic neuropathy. Br J Ophthalmol 91: 895-897. (Pubitemid 47013099)
3. Clayton LM, Duncan JS, Sisodiya SM, &, Acheson JF, (2009): Delayed, rapid visual field loss in a patient after ten years of vigabatrin therapy. Eye 24: 185-186.
4. Conway M, Cubbidge RP, &, Hosking SL, (2008): Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy. Epilepsia 49: 108-116.
5. Daneshvar H, Racette L, Coupland SG, Kertes PJ, Guberman A, &, Zackon D, (1999): Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophthalmology 106: 1792-1798. (Pubitemid 30194283)
6. Durbin S, Mirabella G, Buncic JR, &, Westall CA, (2009): Reduced grating acuity associated with retinal toxicity in children with infantile spasms on vigabatrin therapy. Invest Ophthalmol Vis Sci 50: 4011-4016.
7. Eke T, Talbot JF, &, Lawden MC, (1997): Severe persistent visual field constriction associated with vigabatrin. BMJ 314: 180-181. (Pubitemid 27037871)
8. Eklund SE, Moskowitz A, Barnaby AM, Hansen RM, &, Fulton AB, (2006): The Effect of Vigabatrin on the ERG in Patients With Infantile Spasms. Invest Ophthalmol Vis Sci 47: ARVO E-Abstract 1657.
9. Frisen L, &, Malmgren K, (2003): Characterization of vigabatrin-associated optic atrophy. Acta Ophthalmol Scand 81: 466-473. (Pubitemid 37265665)
10. Harding GF, Wild JM, Robertson KA, Rietbrock S, &, Martinez C, (2000a): Separating the retinal electrophysiologic effects of vigabatrin. treatment versus field loss. Am J Ophthalmol 130: 691.
11. Harding GF, Wild JM, Robertson KA, Rietbrock S, &, Martinez C, (2000b): Separating the retinal electrophysiologic effects of vigabatrin: treatment versus field loss. Neurology 55: 347-352. (Pubitemid 30650073)
12. Kalviainen R, &, Nousiainen I, (2001): Visual field defects with vigabatrin: epidemiology and therapeutic implications. CNS Drugs 15: 217-230. (Pubitemid 32281182)
13. Kinirons P, Cavalleri GL, O'Rourke D, Doherty CP, Reid I, Logan P, Liggan B, &, Delanty N, (2006): Vigabatrin retinopathy in an Irish cohort: lack of correlation with dose. Epilepsia 47: 311-317.
14. Kjellstrom U, Lovestam-Adrian M, Andreasson S, &, Ponjavic V, (2008): Full-field ERG and visual fields in patients 5 years after discontinuing vigabatrin therapy. Doc Ophthalmol 117: 93-101.
15. Krauss GL, Johnson MA, &, Miller NR, (1998): Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology 50: 614-618.
16. Lawden MC, Eke T, Degg C, Harding GF, &, Wild JM, (1999): Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry 67: 716-722.
17. Lawthom C, Smith PE, &, Wild JM, (2009): Nasal retinal nerve fiber layer attenuation: a biomarker for vigabatrin toxicity. Ophthalmology 116: 565-571.
18. Malmgren K, Ben-Menachem E, &, Frisen L, (2001): Vigabatrin visual toxicity: evolution and dose dependence. Epilepsia 42: 609-615. (Pubitemid 32453643)
19. McDonagh J, Grierson DJ, Keating D, &, Parks S, (2001): The wide field multifocal ERG reveals a retinal defect caused by vigabatrin toxicity? Br J Ophthalmol 85: 110.
20. Midelfart A, Midelfart E, &, Brodtkorb E, (2000): Visual field defects in patients taking vigabatrin. Acta Ophthalmol Scand 78: 580-584.
21. Moreno MC, Giagante B, Saidon P, Kochen S, Benozzi J, &, Rosenstein RE, (2005): Visual defects associated with vigabatrin: a study of epileptic argentine patients. Can J Neurol Sci 32: 459-464. (Pubitemid 41788904)
22. Nousiainen I, Mantyjarvi M, &, Kalviainen R, (2001): No reversion in vigabatrin-associated visual field defects. Neurology 57: 1916-1917. (Pubitemid 33096710)
23. Ravindran J, Blumbergs P, Crompton J, Pietris G, &, Waddy H, (2001): Visual field loss associated with vigabatrin: pathological correlations. J Neurol Neurosurg Psychiatry 70: 787-789. (Pubitemid 32554211)
24. Russell-Eggitt IM, Mackey DA, Taylor DS, Timms C, &, Walker JW, (2000): Vigabatrin-associated visual field defects in children. Eye 14 (Pt 3A): 334-339. (Pubitemid 30479707)
25. Schechter PJ, (1989): Clinical pharmacology of vigabatrin. Br J Clin Pharmacol 27 (Suppl 1): 19S-22S. (Pubitemid 19180357)
26. Tanito M, Kaidzu S, Ohira A, &, Anderson RE, (2008): Topography of retinal damage in light-exposed albino rats. Exp Eye Res 87: 292-295.
27. Wild JM, Martinez C, Reinshagen G, &, Harding GF, (1999): Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 40: 1784-1794.
28. Wild JM, Robson CR, Jones AL, Cunliffe IA, &, Smith PE, (2006): Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer. Invest Ophthalmol Vis Sci 47: 917-924. (Pubitemid 46768322)
29. Willmore LJ, Abelson MB, Ben-Menachem E, Pellock JM, &, Shields WD, (2009): Vigabatrin: 2008 update. Epilepsia 50: 163-173.